This article was originally published in The Gray Sheet
Executive SummarySalt Lake City-based firm is reducing its payroll "by approximately 33% along with related expense reductions," the company says March 19. The firm is attempting to conserve financial resources because of anticipated delays in the FDA approval process for its Ivox intravascular oxygenator. CardioPulmonics projects that a PMA for the Ivox will be filed by the end of May. In response to the "Temple Report" on FDA's device approval process ("The Gray Sheet" March 8, p. 4), the firm has revised its planned PMA submission to include a "comparison group against which Ivox treated patients can be measured" and expects that FDA review of the application will be "lengthy." The company also reported financial results for the fiscal year ended Dec. 31. The firm had a net loss of $6.3 mil., compared to a loss of $4.2 mil. for fiscal year 1991. Revenues were $133,198, down from $376,366 in 1991. CardioPulmonics notes that the decreased revenues reflect the "wind down" of Ivox clinicals in the U.S. and Europe.
You may also be interested in...
CMR Surgical CEO Martin Frost is making way for a new boss to lead the surgical robotics company. Per Vegard Nerseth is set to join CMR Surgical in January 2020 as the company gears up for its most ambitious year yet.
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.